



| HPAP | 081 | UNOS | |
|---------------------|-------------------------|-----------------------------|-----------------------------|
| Recovery OPO | NDRI | Allocation Via | UPENN □ nPOD ⊠ |
| Age (years) | 45 | DCD | YES □ NO ⊠ |
| Race | Caucasian | DBD | YES ⊠ NO □ |
| Sex | M □ F⊠ | Admission to Cross Clamp | 114 Hours 37 Mins. |
| ABO (Rh) | A1 | Cross Clamp Time | 01/26/2021 18:37 EST |
| BMI (Kg/m²) | 28.906 | Cold Ischemia | 14 Hours 54 Mins. |
| Weight (kg) | 74 | Time* | |
| Height (cm) | 160 | | |
| Cause of Death | Cerebrovascular/Stroke | Preservation | UW ⊠ HTK⊠ |
| | | Solution | Fresh/HTK, UW/SPS-1 |
| Mechanism of Injury | Intracranial Hemorrhage | Organs Recovered | Heart □ Kidney ⊠ |
| | / Stroke | | Lung □ Pancreas ⊠ |
| | | | Liver ⊠ Intestine □ |
| Cardiac | Yes □ | Intraoperative time | |
| Arrest/Downtime | | lapse from liver to | Hours Mins. |
| | No ⊠ | pancreas removal | TIOUIS INTINIS. |
| | | from the | NA |
| | | peritoneal cavity: | IVA |
| CPR / Time | Yes 🗆 | Organs Discarded | Heart □ Kidney □ |
| | | | Lung Pancreas |
| | No ⊠ | | Liver Intestine |
| | | | |
| | | | |
| Total Est. Downtime | No Downtime | Blood Culture | No Growth |
| | | | |
| Date /Time of | 01/22/2021 00:00 EST | PHS High Risk | YES □ NO ⊠ |
| Admission | | | |
| | | Acute Lung Injury | Early pneumonia versus |
| | | | atelectasis left lung base. |
| | | | |

^{*}Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.



Medical History:

| | | Duration | Medications | Compliance | |
|--------------------|---------|------------|---|------------|--|
| Type of Diabetes | T2DM | 20 years | Metformin, Lantus, Trulicity | Unknown | |
| History of cancer | | | | | |
| CAD | Yes | Unknown | Unknown | Unknown | |
| Hypertension | Yes | 10 years | lisinopril | Unknown | |
| Hyperlipidemia | Yes | Unknown | Atorvastatin | Unknown | |
| Autoimmune disease | Unknown | | | | |
| Family History | CAD □ | Diabetes 🗆 | Auto immune disease 🗆 | Others: | |
| | unknown | unknown | unknown | | |
| Surgical History: | Unknown | | | | |
| Comments: | | • | farction, Duration: Unknown ation: Unknown | | |

Hemodynamic Profile

| Average BP During Hospitalization (mmHg) | 131/66 | |
|--|-------------|----------------------------|
| Average Low BP During Hospitalization | 138 / 64 | Duration: 5 Minutes |
| Average BP in OR (mmHg) | NA | |
| Average Low BP in OR (mmHg) | NA | Duration: NA |
| Average HR in OR (bpm) | NA | |
| ABG-pH range | 7.48 – 7.58 | |

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

| Product | Amount (ml) | Units | Total (ml) | |
|---------------------------|-------------|--|------------|--|
| Fresh Frozen Plasma | | | | |
| PRBCs | | | | |
| Platelets | | | | |
| Norepinephrine (Levophed) | | | | |
| Vasopressin | | | | |
| Neo-Synephrine | | | | |
| Epinephrine | | | | |
| Phenylephrine | | | | |
| Dopamine | | 2.5 MCG/KG/MIN started 2 days before organ | | |
| | | recovery for the duration of 19:29:00 hrs | | |



Blood Products/Meds Transfused Intraoperative

| Product | Amount (ml) | Units | Total (ml) |
|--------------------------------|-------------|-------|------------|
| Fresh Frozen Plasma | NA | NA | NA |
| PRBCs | NA | NA | NA |
| Platelets | NA | NA | NA |
| Norepinephrine (Levophed) | NA | NA | NA |
| Vasopressin | NA | NA | NA |
| Neo-Synephrine (phenylephrine) | NA | NA | NA |
| Epinephrine | NA | NA | NA |
| Dopamine | NA | NA | NA |
| Heparin | NA | NA | NA |

Initial Autoantibody Screening (nPOD): ELISA

Not performed for HPAP-T2D program

| GAD-65 | IA-2 |
|--------|------|
| ND | ND |

Confirmatory results: Radioimmuno Assay (RIA)

| | GAD-65 (unit/ml) | IA-2 (unit/ml) | Insulin AAB (unit/ml) | ZnT8 (unit/ml) |
|-----------------------|---------------------|-------------------|--------------------------|-------------------|
| Results | 0 | 0 | 0.068 | - 0.002 |
| Cut-off values | 20 | 5 | 0.010 | 0.020 |

^{*}Sample obtained at time of organ recovery.

| | C-peptide (ng/ml) | Proinsulin |
|---------|----------------------|------------|
| Results | 0.62 | |

^{*}Sample obtained at time of organ recovery.

HLA (OPO)*

| | _ | | | | | | |
|----------|-----|----------|----|----------|------|------------|------------|
| Class 1 | Α | 3 | 25 | Class II | DR | 1 | 17 |
| | В | 8 | 51 | | DR51 | N-Negative | N-Negative |
| | С | 01 | 07 | | DR52 | 52 | |
| | Bw4 | Positive | | | DR53 | N-Negative | N-Negative |
| | Bw6 | Positive | | | DQB1 | 2 | 5 |
| | | | | | DQA1 | 01 | 05 |
| | | | | | DPB1 | 01:01 | 03:01 |
| | | | | | | | |
| Comment: | _ | | | | | | |



Confirmatory HLA (UPENN)*

Not performed for HPAP-T2D program

| Class 1 | Α | | Class II | DRB1 | |
|---------|---|--|----------|------|--|
| | В | | | DRB3 | |
| | С | | | DRB4 | |
| | | | | DRB5 | |
| | | | | DQB1 | |
| | | | | DQA1 | |
| | | | | DPB1 | |
| | | | | DPA1 | |

^{*}HLA typing performed using NGS

Infectious Disease Serology

| | | Hemo/Plasma | Dilution Status |
|----------------------|----------|-------------|-----------------|
| Test | Result | Qualified | Non-Qualified |
| EBV IgG | Positive | ✓ | |
| EBV IgM | Negative | ✓ | |
| CMV | Negative | ✓ | |
| HBcAb | Negative | ✓ | |
| HBsAg | Negative | ✓ | |
| HCV Ab | Negative | ✓ | |
| HIV I/II | Negative | ✓ | |
| Syphilis | Negative | ✓ | |
| Procleix Ultrio | ND | | |
| Ultrio HBV (HBV NAT) | Negative | ✓ | |
| Ultrio HCV (HCV NAT) | Negative | ✓ | |
| Ultrio HIV (HIV NAT) | Negative | √ | |
| Toxoplasma Ab | Negative | ✓ | |
| SARS-CoV-2 | Negative | ✓ | |



Laboratory Panel

| | Initial | Peak | Terminal |
|-------------------------------|---------|------|----------|
| Na (mEq/L) (135-145) | 139 | 152 | 150 |
| Creatinine (<1.5) | 0.73 | 0.73 | 0.57 |
| Glucose (mg/dL) (60-150) | 206 | 467 | 164 |
| HbA1C% | 7.9 | | |
| Total bilirubin (0-1.0) | 0.4 | 0.4 | 0.1 |
| SGOT (AST) (0-40) | 15 | 15 | 12 |
| SGPT (ALT) (5-35) | 17 | 17 | 12 |
| Alkaline phosphatase (45-110) | 119 | 119 | 116 |
| Serum Amylase (23-851) | 16 | | |
| Serum Lipase (0-80) | 6 | | |
| WBC (THO/uL) (4.5-11.0) | 13.8 | 14.7 | 12.5 |
| Hgb (g/dL) (12-16) | 15.4 | 15.4 | 11.2 |
| Platelets (THO/uL) (150-350) | 399 | 399 | 260 |
| INR (<2.0) | 1.3 | | |

Urinalysis

| | 1 st | 2 nd | 3 rd | 4 th |
|---------|-----------------|-----------------|-----------------|-----------------|
| Glucose | Positive: +2 | Positive: +2 | | |

Medications During Hospitalization

| Steroids** | | | |
|----------------------------|--|---------|--|
| Diuretics | | | |
| T3 Protocol | | | |
| T4 Protocol* | | | |
| Insulin** | | | |
| Antihypertensive | | | |
| Vasodilators | | | |
| DDAVP** | | | |
| Total parenteral nutrition | | | |
| Other | | Specify | |

^{*}T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015:7 17-27.

^{**} Excluding T4 Protocol